Assembly Biosciences Inc ASMB
News
Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus
Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026
Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference
Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program With Gilead
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program

